JP2009269923A5 - - Google Patents

Download PDF

Info

Publication number
JP2009269923A5
JP2009269923A5 JP2009185305A JP2009185305A JP2009269923A5 JP 2009269923 A5 JP2009269923 A5 JP 2009269923A5 JP 2009185305 A JP2009185305 A JP 2009185305A JP 2009185305 A JP2009185305 A JP 2009185305A JP 2009269923 A5 JP2009269923 A5 JP 2009269923A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
formulation
unit dose
less
tobramycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009185305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009269923A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2009269923A publication Critical patent/JP2009269923A/ja
Publication of JP2009269923A5 publication Critical patent/JP2009269923A5/ja
Pending legal-status Critical Current

Links

JP2009185305A 2001-05-18 2009-08-07 アミノグリコシド抗生物質の吸入投与のための方法および単位用量処方物 Pending JP2009269923A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29223401P 2001-05-18 2001-05-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2002590936A Division JP2004534763A (ja) 2001-05-18 2002-05-17 アミノグリコシド抗生物質の吸入投与のための方法および単位用量処方物

Publications (2)

Publication Number Publication Date
JP2009269923A JP2009269923A (ja) 2009-11-19
JP2009269923A5 true JP2009269923A5 (https=) 2010-09-02

Family

ID=23123791

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002590936A Pending JP2004534763A (ja) 2001-05-18 2002-05-17 アミノグリコシド抗生物質の吸入投与のための方法および単位用量処方物
JP2009185305A Pending JP2009269923A (ja) 2001-05-18 2009-08-07 アミノグリコシド抗生物質の吸入投与のための方法および単位用量処方物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002590936A Pending JP2004534763A (ja) 2001-05-18 2002-05-17 アミノグリコシド抗生物質の吸入投与のための方法および単位用量処方物

Country Status (11)

Country Link
US (8) US20030143162A1 (https=)
EP (2) EP1320355B1 (https=)
JP (2) JP2004534763A (https=)
AT (1) ATE322249T1 (https=)
AU (1) AU2010210026A1 (https=)
CA (1) CA2447600C (https=)
DE (1) DE60210402T2 (https=)
DK (1) DK1320355T3 (https=)
ES (1) ES2261735T3 (https=)
PT (1) PT1320355E (https=)
WO (1) WO2002094217A1 (https=)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
US20030143162A1 (en) 2001-05-18 2003-07-31 Speirs Robert John Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US20040022740A1 (en) * 2001-07-10 2004-02-05 Baker William R. Macrolide formulations for inhalation and methods of treatment of endobronchial infections
CA2456746A1 (en) * 2001-08-20 2003-02-27 Transave, Inc. Method for treating lung cancers
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
US8245708B2 (en) * 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US7607436B2 (en) * 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
EP1545459A4 (en) * 2002-08-02 2007-08-22 Transave Inc PLATINUM AGGREGATES, AND METHOD FOR MANUFACTURING THE SAME
AU2002953095A0 (en) * 2002-11-29 2002-12-19 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
EP1638549A4 (en) * 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
NZ546821A (en) * 2003-10-15 2009-04-30 Pari Pharma Gmbh Liquid preparation containing tobramycin
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
CA2559722A1 (en) * 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
ES2388420T3 (es) * 2004-05-17 2012-10-15 Gilead Sciences, Inc. Combinación de fosfomicina/aminoglucósido aerosolizada para el tratamiento de las infecciones respiratorias bacterianas
WO2005112957A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
WO2006002178A1 (en) 2004-06-18 2006-01-05 Novartis Vaccines And Diagnostics Inc. Methods of treatment of endobronchial infections
MX2007004955A (es) * 2004-11-08 2007-06-14 Transave Inc Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
WO2007041156A2 (en) * 2005-09-29 2007-04-12 Nektar Therapeutics Antibiotic formulations, unit doses, kits, and methods
AU2013206401B2 (en) * 2005-09-29 2016-06-23 Novartis Ag Antibiotic formulations, unit doses, kits, and methods
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056263A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070190181A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously
WO2007064658A2 (en) * 2005-11-30 2007-06-07 Transave, Inc. Safe and effective methods of administering therapeutic agents
EP3067047B1 (en) 2005-12-08 2022-04-20 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
US8337814B2 (en) * 2005-12-15 2012-12-25 Topical Sinus Therapeutics, Inc. Treatment of active infections, sinusitis, rhinitis, and related neurological disorders and related compositions
JP2008199905A (ja) * 2007-02-16 2008-09-04 Snow Brand Milk Prod Co Ltd 乳酸菌生残性向上剤
EP2214484A4 (en) 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS
CN101981688B (zh) * 2008-04-02 2014-04-02 Imec公司 制造半导体器件的方法以及半导体器件
JP5711135B2 (ja) 2008-10-24 2015-04-30 センプラ ファーマシューティカルズ,インコーポレイテッド 胃腸疾患を治療するための方法
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
ES2608285T3 (es) 2009-09-10 2017-04-07 Cempra Pharmaceuticals, Inc. Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC
MX361413B (es) 2010-03-22 2018-12-05 Cempra Pharmaceuticals Inc Star Formas cristalinas de un macrólido y usos para las mismas.
CN102917708B (zh) 2010-05-20 2015-11-25 森普拉制药公司 制备大环内酯和酮内酯及其中间体的方法
KR102012418B1 (ko) * 2010-07-12 2019-08-20 셀리아 파마슈티칼즈 에이피에스 에어로졸화에 의한 토브라마이신의 투여에 의한 폐 감염의 치료
EP2613630A4 (en) 2010-09-10 2014-01-15 Cempra Pharmaceuticals Inc HYDROGEN BOND FOR THE PREPARATION OF FLUOROCHETOLIDES FOR THE TREATMENT OF DISEASES
US8826904B2 (en) 2011-07-12 2014-09-09 Cardeas Pharma Corporation Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis
KR20140025534A (ko) 2011-07-12 2014-03-04 카르데아스 파마 인코퍼레이티드 아미카신과 포스포마이신 조합물의 제형 및 인공호흡기 관련 폐렴(vap)과 인공호흡기 관련 기도(vat) 기관지염의 치료 방법 및 시스템
NZ700182A (en) 2012-03-27 2017-02-24 Cempra Pharmaceuticals Inc Parenteral formulations for administering macrolide antibiotics
GB201208080D0 (en) 2012-05-09 2012-06-20 Norton Healthcare Ltd Tobramycin formulation
DK2892524T3 (da) 2012-09-04 2021-01-25 Eleison Pharmaceuticals LLC Forebyggelse af pulmonalt kræfttilbagefald med lipid-komplekseret cisplatin
US10124066B2 (en) 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
EP2943503B1 (en) 2013-01-11 2017-08-23 Xellia Pharmaceuticals ApS Polymyxins, compositions, methods of making and methods of use
AU2014239959A1 (en) * 2013-03-14 2015-10-01 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
CN105188712A (zh) 2013-03-15 2015-12-23 森普拉制药公司 用于制备大环内酯抗菌剂的收敛方法
LT3466432T (lt) 2014-05-15 2020-12-28 Insmed Incorporated Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti
EP3166960B1 (en) 2014-07-09 2019-08-07 Xellia Pharmaceuticals ApS Low substituted polymyxins and compositions thereof
US10532080B2 (en) 2014-10-03 2020-01-14 Xellia Pharmaceuticals Aps Sulfomethylated polymixin compositions
JP6626890B2 (ja) 2014-10-03 2019-12-25 クセリア ファーマシューティカルズ エーピーエスXellia Pharmaceuticals ApS 吸入用デバイスおよび同デバイスに含有される水溶液
US10617703B2 (en) 2014-12-10 2020-04-14 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US10898491B2 (en) 2015-12-18 2021-01-26 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11690815B2 (en) 2015-08-05 2023-07-04 Cmpd Licensing Llc Hyperkeratotic skin condition treatments and compositions
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11278590B2 (en) 2015-08-05 2022-03-22 Cmpd Licensing, Llc Compositions and methods for treating nail infections
US10898455B2 (en) 2016-01-07 2021-01-26 Cmpd Licensing, Llc Urea cream formulations
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US9999604B2 (en) 2016-11-17 2018-06-19 Cmpd Licensing, Llc Compounded solutions of diclofenac and lidocaine and methods
US10525025B2 (en) 2016-11-17 2020-01-07 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
JP7449275B2 (ja) 2018-05-02 2024-03-13 インスメッド インコーポレイテッド リポソーム薬物製剤の製造方法
WO2020163416A1 (en) * 2019-02-05 2020-08-13 Mylan Inc Devices and methods for tobramycin inhalation treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993223A (en) 1974-07-25 1976-11-23 American Home Products Corporation Dispensing container
US4502616A (en) 1982-01-04 1985-03-05 Health Care Concepts, Inc. Single use vial
GB8801655D0 (en) 1988-01-26 1988-02-24 Waverley Pharma Ltd Ampoules
ES2038445T3 (es) 1988-01-28 1993-07-16 Lameplast S.R.L. Tiras de ampollas para productos farmaceuticos, cosmeticos y otros.
GB8802349D0 (en) 1988-02-03 1988-03-02 Waverley Pharma Ltd Ampoule with luer
DE3916840A1 (de) 1988-09-21 1990-03-29 Bernd Hansen Ampulle
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
CA2027690A1 (en) 1990-10-18 1992-04-19 Christian Laing Plastic ampul
FR2687066A1 (fr) 1992-02-06 1993-08-13 Oreal Ampoule autocassable.
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5758637A (en) * 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US6083922A (en) * 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US6387886B1 (en) 1998-12-17 2002-05-14 Chiron Corporation Method for the treatment of severe chronic bronchitis (bronchietasis) with an aerosolized antibiotic
SE9902627D0 (sv) * 1999-07-08 1999-07-08 Siemens Elema Ab Medical nebulizer
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
US20030143162A1 (en) 2001-05-18 2003-07-31 Speirs Robert John Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics

Similar Documents

Publication Publication Date Title
JP2009269923A5 (https=)
US10835512B2 (en) Methods of treating respiratory syncytial virus infections
JP2011520911A5 (https=)
JP6429788B6 (ja) 化合物送達のためのデバイス
US20220304980A1 (en) Metered dosing compositions and methods of use of psychedelic compounds
JP5863641B2 (ja) 濃縮肥満細胞安定化用薬学的調合物
JP2010526837A5 (https=)
Henningfield et al. Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
JP2008044951A5 (https=)
NZ585856A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
WO2012040228A3 (en) Aerosol composition for administering drugs
Cazzola et al. Inhaled medication: which device for which patient
JP2006508994A5 (https=)
JP2013522295A5 (https=)
JP6945614B2 (ja) 経鼻投与
JP2006508993A5 (https=)
Keller et al. In-vivo data support equivalent therapeutic efficacy of a new tobramycin inhalation solution (150 mg/1.5 mL) administered by the eFlow® electronic nebuliser compared to TOBI® in the PARI LC PLUS®
RU75944U1 (ru) Аэрозольная форма лекарственного средства
Geller et al. Treatment convenience and satisfaction of tobramycin inhalation powder (TIP) versus TOBI in cystic fibrosis (CF) patients
Konstan et al. Safety and efficacy of tobramycin inhalation powder (TIP) in treating CF patients infected with Pseudomonas aeruginosa (Pa)
Wainwright et al. A double-blind, multinational, randomized, placebo-controlled trial evaluating aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF), mild lung disease and P. aeruginosa (PA)
CN201036611Y (zh) 一种心脏急救药盒
CN104582690A (zh) 用于经鼻部施用的组合物
EA201590323A1 (ru) Способ введения активных веществ в головной мозг